| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
The p53 signature (p53S) has been proposed to be a marker of the earliest phase of development of endometrial serous carcinoma. We examined the presence of p53S in endometriums with menstrual cycle, postmenopausal endometrial glands, endometrial polyps and background endometrium in cases of endometrial carcinoma. As results, p53S was found about 10% of examined endometriums. The presence of p53S was closely associated with postmenopausal endometriums with an advanced age, regardless of endometrial disease. The expression of the GalNac-T6 was a useful marker for histological grade and the good prognosis of the patients with endometrioid adenocarcinoma of the endometrium. The uterine serous and clear carcinomas with positive GalNac-T6 were also shown a better prognosis than those with negative GalNac-T6. BAF57 is involved in ovarian cancer cell growth and sensitivity to anticancer agents. These econstitutional transcriptional factors may be a target for gynecologic cancer therapy.
|
